Multiple sclerosis and fatigue;Esclerosis múltiple y fatiga

Anales del Sistema Sanitario de Navarra

Volumn 23, Issue 3, 2000, Pages 441-450

  De Castro, P ^a   Abad, A ^a   Barcena E ^a   Rotger, A ^a   Iriarte, J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Astenia; Fatigability; Fatigue; Multiple sclerosis

Indexed keywords

AMANTADINE; AMINOPYRIDINE;

ASTHENIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; HUMAN; IMMUNE RESPONSE; IRRITABILITY; MULTIPLE SCLEROSIS; NAUSEA; NEUROPHYSIOLOGY; PARESTHESIA; PYRAMIDAL TRACT; QUALITY OF LIFE; REVIEW;

EID: 17544395309     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Impacto de la fatiga en la esclerosis múltiple: Estudio de una serie de base poblacional en Valladolid
2. Fatigue in MS is associated with specific clinical features
3. Deficiencia, discapacidad y minusvalia en la esclerosis multiple: Un estudio de base poblacional en Valladolid
4. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment
5. Clinical aspects of multiple sclerosis
6. Experiencing symptoms in chronic illness: Fatigue in multiple sclerosis
7. Fatigue in multiple sclerosis
8. The impact of fatigue on patients with multiple sclerosis
9. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus
10. Propuesta de una nueva escala para la evaluación de la fatiga en pacientes con esclerosis múltiple
11. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale
12. The Fatigue Descriptive Scale (FDS): A useful tool to evaluate fatigue in multiple sclerosis
13. A short measure of balance in multiple sclerosis: Validation through Rasch analysis
14. The measurement of fatigue: A new instrument
15. Recent developments in the assessment of quality of life in multiple sclerosis (MS)
16. Reliability and validity of two self-report measures of impairment and disability for MS
17. The objective measurement of fatigue in Multiple Sclerosis
18. The relationship between anaerobic threshold and electromyographic fatigue threshold in college women
19. Central fatigue as revealed by postexercise decrement of motor evoked potentials
20. Bidirectional effect of electromagnetic fields on ketanserin-induced yawning in patients with multiple sclerosis: The role of melatonin
21. Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue
22. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression
23. Serial immune changes in multiple sclerosis patiens under treatment for fatigue
24. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
25. Fatiga y afectación por sistemas funcionales en esclerosis multiple
26. Fatigue in multiple sclerosis: Interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability
27. Lack of a correlation between demyelinating plaques on MRI scan and clinical recovery in multiple sclerosis by treatment with electromagnetic fields
28. Increased energy cost of walking in multiple sclerosis: Effect of spasticity, ataxia, and weakness
29. Energy cost of walking and exertional dyspnea in multiple sclerosis
30. Focal depression of cortical excitability induced by fatiguing muscle contraction: A transcranial magnetic stimulation study
31. Walking and fatigue in multiple sclerosis: The role of the corticospinal system
32. An electrophysiological study of the mechanism of fatigue in multiple sclerosis
33. Myogenic and central neurogenic factors in fatigue in multiple sclerosis
34. Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients
35. Fatigue and magnetic resonance imaging activity in multiple sclerosis
36. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: A 18F-fluorodeoxyglucose positron emission tomography study
37. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: Development of a model
38. Physical activity in chronic fatigue syndrome: Assessment and its role in fatigue
39. Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis
40. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis
41. Fatigue brought on by malfunction of the central and peripheral nervous systems
42. Establishing a physiological basis to multiple sclerosis-related fatigue: A case report
43. Excessive muscular fatigue in patients with spastic paraparesis
44. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis
45. Muscle fiber type-specific myofibrillar actomyosin Ca2+ ATPase activity in multiple sclerosis
46. Dual labelling of circulating CD8 cells in patients with multiple sclerosis
47. Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis
48. Cytokine correlates of fatigue in multiple sclerosis
49. Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic
50. A prospective study of depression and immune dysregulation in multiple sclerosis
51. Endocrine function in multiple sclerosis
52. Assessment of depression in multiple sclerosis patients with severe fatigue
53. Sleep disturbance, fatigue and depression in multiple sclerosis
54. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis
55. Modalities of multiple sclerosis: Correlation with clinical and biological factors
56. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis
57. Amantadine, fatigue, and multiple sclerosis
58. Amantadine treatment of fatigue associated with multiple sclerosis
59. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis
60. Amantadine therapy for fatigue in multiple sclerosis
61. 4-Aminopyridine improves clinical signs in multiple sclerosis
62. Effects of 4-aminopyridine in patients with multiple sclerosis
63. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, crossover study
64. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis
65. Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo
66. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis
67. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
68. Extended outpatient rehabilitation: Its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis
69. Mechanisms and management of fatigue in progressive neurological disorders
70. The experience of fatigue and strategies of self-care among persons with multiple sclerosis